(19)
(11) EP 4 076 660 A1

(12)

(43) Date of publication:
26.10.2022 Bulletin 2022/43

(21) Application number: 20821410.6

(22) Date of filing: 03.12.2020
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07K 16/28(2006.01)
 C07K 16/22(2006.01)
A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/22; C07K 16/2818; A61K 2039/505; A61K 2039/507; A61K 2039/545; A61P 35/00; C07K 16/2803
(86) International application number:
PCT/IB2020/061458
(87) International publication number:
WO 2021/123996 (24.06.2021 Gazette 2021/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 20.12.2019 US 201962951632 P
18.02.2020 US 202062978267 P
22.07.2020 US 202063055230 P
11.10.2020 US 202063090259 P
11.10.2020 US 202063090264 P
23.11.2020 US 202063117206 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • DOSTALEK, Mirek
    4002 Basel (CH)
  • FABRE, Claire
    4002 Basel (CH)
  • KHANSHAN, Fariba
    Cambridge, Massachusetts 02139 (US)

(74) Representative: Bucher, Tamaris Clare et al
Novartis AG Lichtstrasse 35
4056 Basel
4056 Basel (CH)

   


(54) USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES